✦ LIBER ✦

Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment

✍ Scribed by Tatsuya Ide; Ryukichi Kumashiro; Reiichiro Kuwahara; Hiroyuki Koga; Yuriko Koga; Teruko Hino; Kazuo Tanaka; Akiko Hisamochi; Kei Ogata; Michio Sata

Publisher: Springer Japan
Year: 2005
Tongue: English
Weight: 148 KB
Volume: 40
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-005-1597-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon for treatment of breakthrough

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

✍ Fumitaka Suzuki; Akihito Tsubota; Norio Akuta; Takashi Someya; Masahiro Kobayash 📂 Article 📅 2002 🏛 Springer Japan 🌐 English ⚖ 265 KB

Clinical course and predictive factors o

Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients

✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Long-term follow-up of alpha-interferon

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B

✍ Monika van Zonneveld; Pieter Honkoop; Bettina E. Hansen; Hubertus G.M. Niesters; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

Response to long-term lamivudine treatme

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

✍ Mariko Kobayashi; Fumitaka Suzuki; Norio Akuta; Yoshiyuki Suzuki; Yasuji Arase; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 2 views

## Abstract Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], __

Clinical course of spontaneous reactivat

Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B

✍ Philippe Levy; Dr. Patrick Marcellin; Michèle Martinot-Peignoux; Claude Degott; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

The purposes of this study were (a) to describe the clinical and biochemical manifestations associated with spontaneous reactivation of hepatitis B virus as defined by the reappearance of hepatitis B virus DNA in serum using dot-blot hybridization and (b) to determine whether the clinical and bioche

Favorable efficacy of long-term lamivudi

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study

✍ Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Hitomi Sezaki; Tetsuya Hosaka; T 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract The long‐term efficacy of lamivudine therapy in patients with hepatitis B virus (HBV) infection is still not clear. In this study, 20 non‐cirrhotic Japanese patients infected with HBV received lamivudine therapy for more than 1 year and were followed for a median period of 8.5 years (ra